Redmile Group LLC Buys 495,103 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Redmile Group LLC lifted its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by 10.3% during the 1st quarter, HoldingsChannel.com reports. The firm owned 5,296,643 shares of the company’s stock after buying an additional 495,103 shares during the quarter. Deciphera Pharmaceuticals accounts for about 3.1% of Redmile Group LLC’s holdings, making the stock its 7th biggest holding. Redmile Group LLC owned approximately 0.06% of Deciphera Pharmaceuticals worth $83,316,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of DCPH. Fisher Asset Management LLC bought a new position in Deciphera Pharmaceuticals during the 4th quarter worth approximately $1,006,000. Frazier Life Sciences Management L.P. raised its position in shares of Deciphera Pharmaceuticals by 176.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,021,800 shares of the company’s stock valued at $16,482,000 after acquiring an additional 651,800 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Deciphera Pharmaceuticals by 6.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,561,654 shares of the company’s stock valued at $25,191,000 after purchasing an additional 92,410 shares during the last quarter. Armistice Capital LLC raised its position in shares of Deciphera Pharmaceuticals by 12.7% during the 4th quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $83,876,000 after purchasing an additional 588,000 shares during the period. Finally, Nebula Research & Development LLC lifted its holdings in shares of Deciphera Pharmaceuticals by 93.4% in the 4th quarter. Nebula Research & Development LLC now owns 64,159 shares of the company’s stock worth $1,035,000 after purchasing an additional 30,990 shares during the last quarter. 70.96% of the stock is currently owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Price Performance

Shares of DCPH remained flat at $25.59 during mid-day trading on Monday. 600 shares of the stock traded hands, compared to its average volume of 1,292,551. The company has a fifty day moving average of $25.57 and a 200-day moving average of $19.96. Deciphera Pharmaceuticals, Inc. has a 12 month low of $9.90 and a 12 month high of $25.61. The company has a market cap of $2.21 billion, a PE ratio of -11.58 and a beta of 0.19.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its earnings results on Friday, May 10th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. Deciphera Pharmaceuticals had a negative net margin of 108.86% and a negative return on equity of 52.42%. The firm had revenue of $45.00 million during the quarter, compared to analysts’ expectations of $45.99 million. Equities research analysts forecast that Deciphera Pharmaceuticals, Inc. will post -2.15 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on DCPH shares. Guggenheim restated a “neutral” rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday, April 30th. Leerink Partnrs cut shares of Deciphera Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, April 29th. JMP Securities reissued a “market perform” rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday, April 30th. Barclays upgraded shares of Deciphera Pharmaceuticals from an “underweight” rating to an “equal weight” rating and boosted their price target for the stock from $9.00 to $26.00 in a research report on Tuesday, April 30th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $25.60 price objective (down from $26.00) on shares of Deciphera Pharmaceuticals in a report on Monday, April 29th. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Deciphera Pharmaceuticals has a consensus rating of “Hold” and an average target price of $24.17.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.